Сосудистые протезы с противомикробным покрытием: экспериментальные разработки и внедрение в клиническую практику

Цель. Одна из проблем сердечно-сосудистой хирургии - инфицирование сосудистого протеза, сопровождающееся тяжелыми осложнениями и высокими показателями смертности. Создание сосудистых протезов с антимикробным покрытием, способным защитить имплантат от инфицирования, является очень актуальным направлением. В настоящем обзоре освещены причины возникновения антибиотикорезистентности, описаны основные существующие направления создания сосудистых протезов с противомикробным покрытием, обозначены перспективы использования антимикробных пептидов и катионных амфифилов при создании антимикробного покрытия, к которому у патогенных микроорганизмов не развивается резистентности.

1. Pelletier-Galarneau M., Juneau D. Vascular graft

2. Phang D., Smeds M.R., Abate M., Ali A., Long B., Rahimi infection: Improving diagnosis with functional imaging. J. M., Giglia J., Bath J. Revascularization with Obturator or Nucl. Cardiol. 2020: 1-5. DOI: 10.1007/s12350-020-02269-z. Hemi-neoaortoiliac System for Partial Aortic Graft Infections. Ann Vasc Surg. 2019; 54: 166-175 DOI: 10.1016/j.avsg.2018.06.012.

3. Gentili A., Di Pumpo M., La Milia D.I., Vallone D., Vangi G., Corbo M.I., Berloco F., Cambieri A., Damiani G., Ricciardi W., Laurenti P. A Six-Year Point Prevalence Survey of Healthcare-Associated Infections in an Italian Teaching Acute Care Hospital. Int J Environ Res Public Health. 2020; 17(21): 7724. DOI: 10.3390/ijerph17217724.

4. Ulloa E.R., Singh K.V., Geriak M., Haddad F., Murray B.E., Nizet V, Sakoulas G. Cefazolin and Ertapenem Salvage Therapy Rapidly Clears Persistent Methicillin-Susceptible Staphylococcus aureus Bacteremia. Clin Infect Dis. 2020; 71(6): 1413-1418. DOI: 10.1093/cid/ciz995.

5. Siracuse J.J, Nandivada P., Giles K.A., Hamdan AD, Wyers MC, Chaikof EL, Pomposelli FB, Schermerhorn ML. Prosthetic graft infections involving the femoral artery. J Vasc Surg. 2013; 57(3):700-705. DOI: 10.1016/j.jvs.2012.09.049.

6. Andercou O., Marian D., Olteanu G., Stancu B., Cucuruz B. , Noppeney T. Complex treatment of vascular prostheses infections. Medicine (Baltimore). 2018; 97(27): e11350. DOI: 10.1097/MD.0000000000011350.

7. Livermore D.M. Has the era of untreatable infections arrived? J Antimicrob Chemother. 2009; 64: 29-36. DOI: 10.1093/jac/dkp255..

8. Menger M.D., Hammersen F., Messmer K. In vivo assessment of neovascularization and incorporation of prosthetic vascular biografts. Thorac Cardiovasc Surg. 1992; 40(1): 19-25. DOI: 10.1055/s-2007-1020105.

9. Mourino V., Cattalini J.P., Boccaccini A.R. Metallic ions as therapeutic agents in tissue engineering scaffolds: an overview of their biological applications and strategies for new developments. J R Soc Interface. 2012; 9(68): 401-419. DOI: 10.1098/rsif.2011.0611.

10. Berard X., Puges M., Pinaquy J.B., Cazanave C., Stecken L. , Bordenave L., Pereyre S., M'Zali F. In vitro Evidence of Improved Antimicrobial Efficacy of Silver and Triclosan Containing Vascular Grafts Compared with Rifampicin Soaked Grafts. Eur J Vasc Endovasc Surg. 2019; 57(3):424-432. DOI: 10.1016/j.ejvs.2018.08.053.

11. Honig S., Seeger P., Rohde H., Kolbel T., Debus E.S., Diener H. Efficacy of antiseptic impregnation of aortic endografts with rifampicin compared to silver against in vitro contamination with four bacteria that frequently cause vascular graft infections. JVS: Vascular Science. 2020; 1: 181-189. DOI: 10.1016/j.jvssci.2020.06.003.

12. Larena-Avellaneda A., Russmann S., Fein M., Debus E.S. Prophylactic use of the silver-acetate-coated graft in arterial occlusive disease: a retrospective, comparative study. J Vasc Surg. 2009; 50(4):790-798. DOI: 10.1016/j.jvs.2009.05.003.

13. Jeanmonod P., Laschke M.W., Gola N., von Heesen M. , Glanemann M., Menger M.D., Moussavian M.R. Early host tissue response to different types of vascular prostheses coated with silver acetate or vaporized metallic silver. Eur J Vasc Endovasc Surg. 2014; 47(6): 680-688. DOI: 10.1016/j.ejvs.2014.03.006.

14. Butany J., Leask R.L., Desai N.D., Jegatheeswaran A., Silversides C., Scully H.E., Feindel C. Pathologic analysis of 19 heart valves with silver-coated sewing rings. J Card Surg. 2006; 21(6): 530-538. DOI: 10.1111/j.1540-8191.2006.00323.x.

15. Qiao M., Ying G.G., Singer A.C., Zhu Y.G. Review of antibiotic resistance in China and its environment. Environ Int. 2018; 110:160-172. DOI: 10.1016/j.envint.2017.10.016.

16. Schmacht D., Armstrong P., Johnson B., Pierre K., Back M., Honeyman A., Cuthbertson D., Bandyk D. Graft infectivity of rifampin and silver-bonded polyester grafts to MRSA contamination. Vasc Endovascular Surg. 2005; 39(5): 411- 420. DOI: 10.1177/153857440503900505.

17. Hernandez-Richter T., Schardey H.M., Wittmann F., Mayr S., Schmitt-Sody M., Blasenbreu S., Heiss M.M., Gabka C. , Angele M.K. Rifampin and Triclosan but not silver is effective in preventing bacterial infection of vascular Dacron graft material. Eur J Vasc Endovasc Surg. 2003; 26(5): 550557. DOI: 10.1016/s1078-5884(03)00344-7.

18. Powell T.W., Burnham S.J., Johnson G.Jr. A passive system using rifampin to create an infection-resistant vascular prosthesis. Surgery. 1983; 94(5): 765-769.

19. Moussavian M.R., Laschke M.W., Schlachtenberger G., von Heesen M., Wagner M., Glanemann M., Menger M.D. Perigraft vascularization and incorporation of implanted Dacron prostheses are affected by rifampicin coating. J Vasc Surg. 2016; 64(6): 1815-1824. DOI: 10.1016/j.jvs.2015.07.104.

20. Goёau-Brissonniёre O., Leport C., Bacourt F., Lebrault C., Comte R., Pechere J.C. Prevention of vascular graft infection by rifampin bonding to a gelatin-sealed Dacron graft. Ann Vasc Surg. 1991; 5(5): 408-412. DOI: 10.1007/BF02133043.

21. Gahtan V., Esses G.E., Bandyk D.F., Nelson R.T., Dupont E., Mills J.L. Antistaphylococcal activity of rifampin-bonded gelatin-impregnated Dacron grafts. J Surg Res. 1995; 58(1): 105-10. DOI: 10.1006/jsre.1995.1017.

22. Avramovic J., Fletcher J.P. Prevention of prosthetic vascular graft infection by rifampicin impregnation of a protein-sealed Dacron graft

23. Koshiko S., Sasajima T., Muraki S., Azuma N., Yamazaki K., Chiba K., Tachibana M., Inaba M. Limitations in the use of rifampicin-gelatin grafts against virulent organisms. J Vasc Surg. 2002; 35(4): 779-785. DOI: 10.1067/mva.2002.121850.

24. Clemens M.S., Stull M.C., Hata K.W., Heafner T.A., Watson J.D.B, Arthurs Z.M., Propper B.W. Antimicrobial-bonded graft patency in the setting of a polymicrobial infection in swine (Sus scrofa). J Vasc Surg. 2017; 66(4): 1210-1216. DOI: 10.1016/j.jvs.2016.09.040.

25. Javerliat I., Goёau-Brissonniёre O., Sivadon-Tardy V, Coggia M., Gaillard J.L. Prevention of Staphylococcus aureus graft infection by a new gelatin-sealed vascular graft prebonded with antibiotics. J Vasc Surg. 2007; 46(5): 1026-1031. DOI: 10.1016/j.jvs.2007.06.023.

26. Sardelic F., Ao P. Y., Fletcher J.P. Rifampicin impregnated Dacron grafts: no development of rifampicin resistance in an animal model. Eur J Vasc Endovasc Surg. 1995; 9(3): 314-318. DOI: 10.1016/s1078-5884(05)80137-6.

27. Sacar M., Goksin I., Baltalarli A., Turgut H., Sacar S., Onem G., Ozcan V., Adali F. The prophylactic efficacy of rifampicin-soaked graft in combination with systemic vancomycin in the prevention of prosthetic vascular graft infection: an experimental study. J Surg Res. 2005; 129(2): 329-334. DOI: 10.1016/j.jss.2005.05.017.

28. Bisdas T., Beckmann E., Marsch G., Burgwitz K., Wilhelmi M., Kuehn C., Haverich A., Teebken O.E. Prevention of vascular graft infections with antibiotic graft impregnation prior to implantation: in vitro comparison between daptomycin, rifampin and nebacetin. Eur J Vasc Endovasc Surg. 2012; 43(4): 448-456. DOI: 10.1016/j.ejvs.2011.12.029.

29. Haverich A., Hirt S., Karck M., Siclari F., Wahlig H. Prevention of graft infection by bonding of gentamycin to Dacron prostheses. J Vasc Surg. 1992; 15(1): 187-193. DOI: 10.1067/mva.1992.30301.

30. Salmoukas C, Ruemke S, Rubalskii E, Burgwitz K, Haverich A, Kuehn C. Vascular Graft Pre-Treatment with Daptomycin Prior to Implantation Prevents Graft Infection with Staphylococcus aureus in an In Vivo Model. Surg Infect (Larchmt). 2020; 21(2): 161-168. DOI:10.1089/sur.2019.124.

31. Lehnhardt F.J., Torsello G., Claeys L.G., Pfeiffer M., Wachol-Drewek Z., Grundmann R.T., Sandmann W. Systemic and local antibiotic prophylaxis in the prevention of prosthetic vascular graft infection: an experimental study. Eur J Vasc Endovasc Surg. 2002; 23(2): 127-33. DOI: 10.1053/ejvs.2001.1571.

32. Manouguian S. Clinical experience with a new antimicrobially coated InterGard-IgK/AM vascular prosthesis in surgical treatment of deep wound infection with involvement of the synthetic bypass: report of 2 cases. Zentralblatt fur Chirurgie. 1996; 121(9): 768-772; discussion 772-773.

33. Hernandez-Richter T., Schardey H.M., Lohlein F., Fleischer C.T., Walli A.K., Boos K.S., Schildberg F.W. Binding kinetics of triclosan (Irgasan) to alloplastic vascular grafts: an in vitro study. Annals of Vascular Surgery. 2000; 14(4): 370-375. DOI: 10.1007/s100169910065.

34. Schneider F., O'Connor S., Becquemin J.P. Efficacy of collagen silver-coated polyester and rifampin-soaked vascular grafts to resist infection from MRSA and Escherichia coli in a dog model. Ann Vasc Surg. 2008; 22(6): 815-821. DOI: 10.1016/j.avsg.2008.06.011.

35. Berard X, Stecken L, Pinaquy JB, Cazanave C, Puges M, Pereyre S, Bordenave L, M'Zali F. Comparison of the Antimicrobial Properties of Silver Impregnated Vascular Grafts with and without Triclosan. Eur J Vasc Endovasc Surg. 2016; 51(2): 285-92. DOI: 10.1016/j.ejvs.2015.10.016.

36. Авхутская Г.С., Сенчик И.Ю., Кравцова И.А., Михайлова Т.С., Кузнецова О.Г, Фролова О.С. Исследование свойств протезов кровеносных сосудов из лавсана, обработанных антимикробной композицией с введением метронидазола. Ученые записки СПбГМУ им. И.П. Павлова. 2008; 4.

37. Aboshady I., Raad I., Shah A.S., Vela D., Dvorak T., Safi H.J., Buja L.M., Khalil K.G. A pilot study of a triple antimicrobial-bonded Dacron graft for the prevention of aortic graft infection. J Vasc Surg. 2012; 56(3): 794-801. DOI: 10.1016/j.jvs.2012.02.008.

38. Aboshady I., Raad I., Vela D., Hassan M., Aboshady Y, Safi H.J., Buja L.M., Khalil K.G. Prevention of perioperative vascular prosthetic infection with a novel triple antimicrobial-bonded arterial graft. J Vasc Surg. 2016; 64(6): 1805-1814. DOI: 10.1016/j.jvs.2015.09.061.

39. Yu D.G., Zhu L.M., White K., Branford-White C. Electrospun nanofiber-based drug delivery systems. Health. 2009; 1(02): 67. DOI: 10.4236/health.2009.12012.

40. Yu D.G., Zhou J., Chatterton N.P., Li Y, Huang J., Wang X. Polyacrylonitrile nanofibers coated with silver nanoparticles using a modified coaxial electrospinning process. Int J Nanomedicine. 2012; 7: 5725-5732. DOI: 10.2147/IJN.S37455.

41. Kim K., Luu Y.K., Chang C., Fang D., Hsiao B.S., Chu B., Hadjiargyrou M. Incorporation and controlled release of a hydrophilic antibiotic using poly(lactide-co-glycolide)-based electrospun nanofibrous scaffolds. J Control Release. 2004; 98(1): 47-56. DOI: 10.1016/j.jconrel.2004.04.009.

42. Liu K.S., Lee C.H., Wang Y.C., Liu S.J. Sustained release of vancomycin from novel biodegradable nanofiber-loaded vascular prosthetic grafts: in vitro and in vivo study. Int J Nanomedicine. 2015; 10: 885-891. DOI: 10.2147/IJN.S78675.

43. Matsuzaki K. Control of cell selectivity of antimicrobial peptides. Biochim Biophys Acta. 2009; 1788(8): 1687-92. DOI:10.1016/j.bbamem.2008.09.013.

44. Ikeda T., Tazuke S. Biologically active polycations: Antimicrobial activities of Poly[trialkyl(vinylbenzyl) ammonium chloride]-type polycations . Die Makromol. Chem. Rapid Commun. 1983; (4): 459-461.

45. Gelman M.A., Weisblum B., Lynn D.M., Gellman S.H. Biocidal activity of polystyrenes that are cationic by virtue of protonation. Org Lett. 2004; 6(4): 557-60. DOI: 10.1021/ol036341+.

46. Vigliotta G., Mella M., Rega D., Izzo L. Modulating antimicrobial activity by synthesis: dendritic copolymers based on nonquaternized 2-(dimethylamino)ethyl methacrylate by Cu-mediated ATRP. Biomacromolecules. 2012; 13(3): 833-41. DOI: 10.1021/bm2017349.

47. Haney E.F., Mansour S.C., Hancock R.E. Antimicrobial Peptides: An Introduction. Methods Mol Biol. 2017; 1548: 3-22. DOI: 10.1007/978-1-4939-6737-7_1. PMID: 28013493.

48. Fan L., Sun J., Zhou M., Zhou J., Lao X., Zheng H., Xu H. DRAMP: a comprehensive data repository of antimicrobial peptides. Sci Rep. 2016; 6: 24482. DOI: 10.1038/srep24482.

49. Kang X., Dong F., Shi C., Liu S., Sun J., Chen J., Li H., Xu H., Lao X., Zheng H. DRAMP 2.0, an updated data repository of antimicrobial peptides. Sci Data. 2019; 6(1): 148. DOI: 10.1038/s41597-019-0154-y.

50. Ciumac D., Gong H., Hu X., Lu J.R. Membrane targeting cationic antimicrobial peptides. J Colloid Interface Sci. 2019; 537: 163-185. DOI: 10.1016/j.jcis.2018.10.103..

51. Scocchi M., Mardirossian M., Runti G., Benincasa M. Non-Membrane Permeabilizing Modes of Action of Antimicrobial Peptides on Bacteria. Curr Top Med Chem. 2016; 16(1): 76-88. DOI: 10.2174/1568026615666150703121009.

52. Le C.F., Fang C.M., Sekaran S.D. Intracellular Targeting Mechanisms by Antimicrobial Peptides. Antimicrob Agents Chemother. 2017; 61(4): e02340-16. DOI: 10.1128/AAC.02340-16.

53. Andersson D.I., Hughes D., Kubicek-Sutherland J.Z. Mechanisms and consequences of bacterial resistance to antimicrobial peptides. Drug Resist Updat. 2016; 26: 43-57. DOI: 10.1016/j.drup.2016.04.002.

54. Molchanova N., Hansen P.R., Franzyk H. Advances in Development of Antimicrobial Peptidomimetics as Potential Drugs. Molecules. 2017; 22(9): 1430. DOI: 10.3390/molecules22091430.

55. Xue Y, Xiao H., Zhang Y Antimicrobial polymeric materials with quaternary ammonium and phosphonium salts. Int J Mol Sci. 2015; 16(2): 3626-3655. DOI: 10.3390/ijms16023626.